UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 80

Sortiert nach

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Cancer, 2016-06, Vol.122 (12), p.1871-1879

2016

Volltextzugriff (PDF)

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design

Future oncology (London, England), 2022-03, Vol.18 (7), p.781-791

2022

Volltextzugriff (PDF)

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2044-2051

2006

Volltextzugriff (PDF)

Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer

Journal of clinical oncology, 2009-04, Vol.27 (12), p.1941-1947

2009

Volltextzugriff (PDF)

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

The lancet oncology, 2009-06, Vol.10 (6), p.549-558

2009

Volltextzugriff (PDF)

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3700-3711

2023

Volltextzugriff (PDF)

Begutachtung Psychischer Störungen

4. Aufl. 2019 edition., 2020

Volltextzugriff (PDF)

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Anti-cancer drugs, 1999-09, Vol.10 (8), p.719-728

1999

Volltextzugriff (PDF)

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3700-3711

2023

Volltextzugriff (PDF)

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Nature communications, 2024-07, Vol.15 (1), p.5763-12, Article 5763

2024

Volltextzugriff (PDF)

Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design

Future oncology (London, England), 2022-03, Vol.18 (7), p.781-791

2022

Volltextzugriff (PDF)

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Future oncology (London, England), 2024-02, Vol.20 (16), p.1047-1055

2024

Volltextzugriff (PDF)

Androgen antagonists: Potential role in prostate cancer prevention

Urology (Ridgewood, N.J.), 2001-04, Vol.57 (4), p.64-67

2001

Volltextzugriff (PDF)

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

Cancer chemotherapy and pharmacology, 2018-03, Vol.81 (3), p.609-614

2018

Volltextzugriff (PDF)

Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Cancer, 2016-03, Vol.122 (12), p.1871-1879

2016

Volltextzugriff (PDF)

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2031-2031

2013

Volltextzugriff (PDF)

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4029-4029

2014

Volltextzugriff (PDF)

Adjuvant chemotherapy after trimodality therapy in locally advanced esophageal cancer

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.144-144

2014

Volltextzugriff (PDF)

Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6005-6005

2014

Volltextzugriff (PDF)

An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.328-328

2012

Volltextzugriff (PDF)

A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4111-4111

2012

Volltextzugriff (PDF)

Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2536-2536

2013

Volltextzugriff (PDF)

GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies

Blood, 2010-11, Vol.116 (21), p.3281-3281

2010

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(73)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(44)
Humans
(31)
Male
(30)
Biological And Medical Sciences
(27)
Female
(18)
Medical Sciences
(18)
Adult
(17)
Middle Aged
(15)
Oncology
(15)
Aged
(13)
Animals
(12)
Fundamental And Applied Biological Sciences. Psychology
(10)
Pharmacology & Pharmacy
(10)
Pharmacology. Drug Treatments
(10)
Rats
(10)
Respiratory System
(9)
Chemotherapy
(7)
Dose-Response Relationship, Drug
(7)
Antineoplastic Agents
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer

Begutachtung Psychischer Störungen

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF V600 -Mutant Metastatic Non-Small-Cell Lung Cancer

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Androgen antagonists: Potential role in prostate cancer prevention

A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC)

Adjuvant chemotherapy after trimodality therapy in locally advanced esophageal cancer

Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN)

An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study

A phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report

Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors

GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Suchergebnisse filtern